SCHEMBL5033277

SCHEMBL5033277

Cc1cc(N2CCCC2)c2cc(F)c(OCc3ccc(C#N)cc3)cc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
MAPT P10636 2/20 0.46
RECQL P46063 1/20 0.46
ALDH1A1 P00352 3/20 0.42
POLB P06746 2/20 0.42
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
NOS3 P29474 1/20 0.42
NOS1 P29475 1/20 0.42
NCF1 P14598 2/20 0.41
HRH3 Q9Y5N1 3/20 0.40
KDM4E B2RXH2 2/20 0.38
HTR6 P50406 2/20 0.38
KIT P10721 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
MAPK1 P28482 1/20 0.37
HSD17B10 Q99714 1/20 0.37
ABCB1 P08183 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5036318 0.90 HTR6 (0.51) NCF1HTR6KITSLC6A9
SCHEMBL5035838 0.88 TSHR (0.46) TSHRNPSR1MAPTRECQLALDH1A1
SCHEMBL5042845 0.88 NCF1 (0.39) TSHRNPSR1MAPTRECQLALDH1A1
SCHEMBL5036061 0.87 NCF1 (0.54) LMNAHTTNCF1HTR6MAPK1
SCHEMBL5521433 0.87 NCF1 (0.42) TSHRNPSR1MAPTRECQLALDH1A1
SCHEMBL5037508 0.83 SPHK2 (0.45) TSHRNPSR1MAPTRECQLALDH1A1
SCHEMBL5037505 0.83 SPHK2 (0.45) TSHRNPSR1MAPTRECQLALDH1A1
SCHEMBL5036075 0.83 MAOB (0.47) TSHRNPSR1MAPTRECQLALDH1A1
SCHEMBL5040453 0.83 NCF1 (0.45) TSHRNPSR1ALDH1A1NCF1KDM4E
SCHEMBL5037525 0.82 HRH3 (0.48) TSHRNPSR1MAPTRECQLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818767-B2 NEUROPEPTIDE Y (NPY) ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS, OR OBESITY HOFFMANN-LA ROCHE INC. 2004-11-16 US claimed
US-20020198194-A1 Quinoline derivatives HOFFMANN-LA ROCHE INC. 2002-12-26 US claimed
EP-1395564-B1 QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR HOFFMANN LA ROCHE (CH) 2008-02-27 EP disclosed
US-20050049413-A1 Quinoline derivatives MUELLER WERNER (CH) 2005-03-03 US disclosed
US-6818767-B2 NEUROPEPTIDE Y (NPY) ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS, OR OBESITY HOFFMANN-LA ROCHE INC. 2004-11-16 US disclosed
US-20020198194-A1 Quinoline derivatives HOFFMANN-LA ROCHE INC. 2002-12-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198194-A1 Quinoline derivatives NPY2R, NPY1R, NPY4R TSHR 203/4885NPSR1 20/4885MAPT 3753/4885
US-20050049413-A1 Quinoline derivatives NPY2R, NPY1R, NPY4R TSHR 203/4885NPSR1 20/4885MAPT 3753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.